How we Conduct the Trials

How We Conduct Trials

Bioscience Americas ...Solutions for a Healthier World.

How We Conduct Trials

GIOSTAR has created the following position papers, policies and case studies to ensure and demonstrate its ethical development of new medicines. Indeed, all of our clinical research must be reviewed by a qualified Independent Ethics Committee or Institutional Review Board.

Clinical Outcome After Stem Cell Transplant for Various Diseases U.S. Patient Survival Outcomes Report!

The U.S. Patient Survival Outcomes Report displays an estimate of patients who are alive after adult stem cell transplant.

The estimates are shown:

  • By disease and length of time after transplant: 1 year, 3 year
  • By the type of donor who provided the cells for transplant:
    • Autologous (the patient’s cells)
    • Related allogeneic (a patient’s sibling or another family member’s cells)
    • Unrelated allogeneic (a volunteer donor’s cells) The cells used for transplant can be from bone marrow, peripheral blood, umbilical cord blood or adipose tissues.  Outcomes data show survival information for transplant patients with a similar disease. The information cannot predict the outcome of any one person. One person’s response to transplant may be very different than another person’s response.  The number of patients evaluated can greatly affect the survival estimate.
  • When only a small number of patients are observed, the estimated outcomes can vary widely.
  • When a large number of patients are observed, the estimate is more reliable.  Survival outcomes only provide a partial picture. A patient’s specific medical condition, health, and previous treatments and other factors must also be considered. Patients should refer questions to their doctor; transplant center staff or another health care professional.

Note: If these patients do not get the stem cell transplants, they probably will not survive.